Pluristem Therapeutics, Inc. (NASDAQ:PSTI)

CAPS Rating: 1 out of 5

Recs

1
Player Avatar jeffrycooks (72.49) Submitted: 6/2/2011 10:35:52 PM : Outperform Start Price: $2.77 PSTI Score: -8.11

Oppenheimer Says 5 bucks, currently in phase two- not so sure I like past behaviors of company, but they have found a worthy cause to seek treatment for with their latest procedure and phase two trials... Would be a great therapy if it works well as trials thus far have shown.

Featured Broker Partners


Advertisement